NCT03374241View on ClinicalTrials.gov

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

September 14, 2018

Study Completion Date

September 14, 2018

Conditions
Obesity
Interventions
BIOLOGICAL

HM15211 or Placebo

Long-acting tri-agonist

Trial Locations (1)

91911

Hanmi Investigative Site, Chula Vista

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY